<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03305471</url>
  </required_header>
  <id_info>
    <org_study_id>DS2330-A-U103</org_study_id>
    <nct_id>NCT03305471</nct_id>
  </id_info>
  <brief_title>DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis</brief_title>
  <official_title>A Phase 1b Study, to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Repeated Doses of DS-2330b Alone and When Co-administered With Sevelamer in Patients on Chronic Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This three-part study will be performed with participants on chronic hemodialysis.

        -  Part A will assess plasma pharmacokinetics of DS2330a (free form of DS2330b) after a
           single dose of powder in bottle (PIB) or tablet formulations of DS2330b

        -  Part B will test the safety, tolerability, and effects on serum phosphate (Pi) of 14-day
           repeated oral doses of DS-2330b PIB when given alone and when given along with sevelamer
           carbonate three times a day

        -  Part C is optional, and will test the effects on serum phosphate (Pi) of 14-day repeated
           oral doses of DS-2330b tablets when given with sevelamer carbonate

      After screening, participants should expect the study to last about 21 days for Part A, and
      46 days for Parts B and C.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part A has a 2-period, open-label, randomized, 2-way crossover design with a single dose of Treatments A1 and A2
Part B participants are randomized with a 2:3:3:3 ratio to Treatment B1, B2, B3, and B4, respectively, using a double-blind, repeated dose, parallel design
Part C is an optional, single-arm, open label, repeated dose design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Masking description is for Part B only - Parts A and C are Open Label, so have no masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part A, Period 1: Maximum concentration (Cmax) of DS-2330a</measure>
    <time_frame>Period 1, Pre-dose to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A, Period 2: Cmax of DS-2330a</measure>
    <time_frame>Period 2, Pre-dose to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A, Period 1: Time to maximum concentration (Tmax) of DS-2330a</measure>
    <time_frame>Period 1, Pre-dose to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A, Period 2: Tmax of DS-2330a</measure>
    <time_frame>Period 2, Pre-dose to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A, Period 1: Area under the drug concentration curve (AUC) for DS-2330a over 24 hours (AUC-24)</measure>
    <time_frame>Period 1, Pre-dose to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A, Period 2: AUC for DS-2330a for DS-2330a over 24 hours (AUC-24)</measure>
    <time_frame>Period 2, Pre-dose to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A, Period 1: AUC at the last observable concentration (AUClast) and to infinity (AUCinf) for DS-2330a</measure>
    <time_frame>Period 1, Pre-dose to 48 hours post-dose</time_frame>
    <description>Categories (with the same unit of measure ng*hr/mL): AUClast, AUCinf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A, Period 2: AUClast and AUCinf for DS-2330a</measure>
    <time_frame>Period 2, Pre-dose to 48 hours post-dose</time_frame>
    <description>Categories (with the same unit of measure ng*hr/mL): AUClast, AUCinf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts B and C: Serum phosphate (Pi) levels before hemodialysis</measure>
    <time_frame>within 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All Parts: Number of trial participants with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>through trial completion (about 15 months)</time_frame>
    <description>TEAEs are adverse events (side effects) associated with taking an investigational product, whether or not they were caused by the investigational product. Clinically significant changes in physical exam findings, vital signs, electrocardiograms, clinical lab tests and thyroid function are recorded as TEAEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Cmax of DS-2330a</measure>
    <time_frame>within 24 hours on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Cmax of DS-2330a</measure>
    <time_frame>within 24 hours on Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Tmax of DS-2330a</measure>
    <time_frame>within 24 hours, Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Tmax of DS-2330a</measure>
    <time_frame>within 24 hours, Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: AUC-24 for DS-2330a</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: AUC-24 for DS-2330a</measure>
    <time_frame>Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: AUCinf for DS-2330a</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: AUCinf for DS-2330a</measure>
    <time_frame>Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Minimum concentration (Ctrough) of DS-2330a</measure>
    <time_frame>within 11 days</time_frame>
    <description>Trough blood levels for DS-2330a will be collected before the morning dose (prior to breakfast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Dialysis clearance of DS-2330a</measure>
    <time_frame>on Day 11</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>Part A: DS-2330b PIB, then Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: DS-2330b Tablet, then PIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants are given placebo three times daily [Treatment B1]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: DS-2330b PIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are given 400 mg of DS-2330b PIB three times daily [Treatment B2]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: DS-2330b PIB + Sevelamer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are given 400 mg of DS-2330b PIB along with 1.6 grams of sevelamer three times daily [Treatment B3]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo + Sevelamer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are given placebo along with 1.6 grams of sevelamer three times daily [Treatment B4]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: DS-2330b Tablet + Sevelamer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are given one 250 mg dose of DS-2330b in tablet form along with 1.6 grams of sevelamer three times daily [Treatment C]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-2330b PIB</intervention_name>
    <description>DS-2330b as powder in bottle with stock solution (PIB)</description>
    <arm_group_label>Part A: DS-2330b PIB, then Tablet</arm_group_label>
    <arm_group_label>Part A: DS-2330b Tablet, then PIB</arm_group_label>
    <arm_group_label>Part B: DS-2330b PIB</arm_group_label>
    <arm_group_label>Part B: DS-2330b PIB + Sevelamer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching stock solution in bottle</description>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_label>Part B: Placebo + Sevelamer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer</intervention_name>
    <description>Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.</description>
    <arm_group_label>Part B: DS-2330b PIB + Sevelamer</arm_group_label>
    <arm_group_label>Part B: Placebo + Sevelamer</arm_group_label>
    <arm_group_label>Part C: DS-2330b Tablet + Sevelamer</arm_group_label>
    <other_name>Sevelamer carbonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-2330b Tablet</intervention_name>
    <description>DS-2330b as tablet formulation</description>
    <arm_group_label>Part A: DS-2330b PIB, then Tablet</arm_group_label>
    <arm_group_label>Part A: DS-2330b Tablet, then PIB</arm_group_label>
    <arm_group_label>Part C: DS-2330b Tablet + Sevelamer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a body mass index (BMI) of 18 kg/m^2 to 40 kg/m^2 (inclusive)

          -  Is on prescribed maintenance hemodialysis (three times a week) for at least 3 months
             before Screening with adequacy demonstrated by a dialysis clearance within 3 months
             before the first dose of the investigational medicinal product

          -  Has permanent vascular access [arteriovenous (A-V) fistula or graft]

          -  Is willing to comply with protocol-specified methods for family planning

          -  For Parts B and C only:

               1. Has protocol-specified acceptable serum Pi levels at Screening and in serum Pi
                  after up to 3 weeks of washout from all Pi binders

               2. Has protocol-specified acceptable serum Ca^2+ level and intact parathyroid
                  hormone (iPTH) level at screening

        Exclusion Criteria:

          -  Is employed by the clinic or the sponsor

          -  Has family relationship with another study participant

          -  Has any history, current condition, or drug use that per protocol or in the opinion of
             the investigator might compromise:

               1. safety of the participant or their children

               2. safety of study staff

               3. analysis of study results

          -  For Parts B and C only:

               1. Is not able to take sevelamer carbonate

               2. Has had partial or total parathyroidectomy within the last six months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>612-852-7006</phone>
      <email>Frank.Terschan@davita.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>407-472-0270</phone>
      <email>cbrown@ocrc.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>612-852-7006</phone>
      <email>Frank.Terschan@davita.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2017</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hemodialysis</keyword>
  <keyword>Investigational drug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

